Basic Information
LncRNA/CircRNA Name | ADPGK-AS1 |
Synonyms | NA |
Region | GRCh38_15:72782835-72798199 |
Ensemble | ENSG00000260898 |
Refseq | NR_040107 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | pancreatic cancer |
ICD-0-3 | C25 |
Methods | Microarray, qPCR, Western blot etc. |
Sample | cell lines (HEK-293T, PANC-1 and SW-1990) |
Expression Pattern | up-regulated |
Function Description | MiR-205-5p was low-expressed while ZEB1 and ADPGK-AS1 were high-expressed in PC tissues and cells compared with the normal.Dual-luciferase reporter gene assay proved that ADPGK-AS1 could directly target miR-205-5p and miR-205-5p could directly target ZEB1 3'UTR. The expression of MiR-205-5p was negatively correlated with proliferation,migration and invasion, and positively correlated with apoptosis rate of PC cells, while ZEB1 and ADPGK-AS1 had an inversed effect. Further in vitro and in vivo investigation indicated that epithelial-mesenchymal transition (EMT) could be restrained by miR-205-5p through targeting ZEB1. ADPGK-AS1 strongly promoted the tumorigenesis via downregulating miR-205-5p expression and induced the EMT process in vivo. ADPGK-AS1 inhibited miR-205-5p and therefore promoted PC progression through activating ZEB1-induced EMT. |
Pubmed ID | 29667486 |
Year | 2018 |
Title | LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition. |
External Links
Links for ADPGK-AS1 | GenBank HGNC NONCODE |
Links for pancreatic cancer | OMIM COSMIC |